of OS factors in this subgroup. Overall, the prognostic value of KIR3DL2 expression in .10% of skin lymphoid cells was detected in the entire cohort but requires further prospective investigation, especially in patients with non-MF/SS CTCL. Altogether, these results identified significant KIR3DL2 expression in all CTCL subtypes, thus expanding the number of candidates for KIR3DL2-targeted therapy. In future clinical studies of IPH4102, patients with all CTCL subtypes should therefore be included. Translational studies of KIR3DL2 involvement in noncutaneous peripheral T-cell lymphomas will also be required to examine whether patients with nonprimary CTCL could benefit from KIR3DL2-targeted therapy. It will also be necessary to assess prospectively whether the clinical effect of IPH4102 is related to the percentage of KIR3DL2 expressing lymphoid cells to optimize the treatment of advanced CTCL.